The first randomized trial of an SGLT2 inhibitor in ADPKD to report a full year of kidney volume data has been published in the Journal of the American Society of Nephrology. Researchers at the University of Colorado and the University of Maryland randomized 50 adults aged 18–55 with ADPKD at high risk of progression, none on tolvaptan, to empagliflozin 25mg daily or placebo for 12 months (NCT05510115).
The trial met its main goals of safety and tolerability: adverse events were similar between groups and 96% of participants in each group tolerated the full dose. But among the secondary outcomes, height-adjusted total kidney volume grew significantly faster on empagliflozin (10.5% per year) than on placebo (5.1% per year; P = 0.001).
Kidney function showed the expected SGLT2 pattern: a faster acute eGFR drop at one month on empagliflozin (−6.2 vs 0.1 mL/min/1.73m²; P = 0.01), then no difference in eGFR change from months 1 to 12 (P = 0.4). There were no between-group differences in vascular stiffness, copeptin, the kidney injury marker KIM-1 or ADPKD symptom scores.
The result adds to growing doubts about SGLT2 inhibitors in ADPKD. A separate Swiss crossover study (SIDIA, Clinical Kidney Journal, October 2026) saw copeptin, a marker of vasopressin, rise 26% after two weeks of empagliflozin. Vasopressin is the hormone that drives cyst growth and that tolvaptan blocks. An August 2026 meta-analysis of six small studies concluded that current evidence is insufficient to establish a benefit.
This was a pilot study, not powered to prove efficacy, and kidney volume was a secondary outcome. The definitive test of the class is the 420-patient STOP-PKD trial of dapagliflozin, which measures long-term kidney function over three years. Until it reports, these findings are a reason for caution about starting an SGLT2 inhibitor specifically to treat ADPKD. Patients already taking one for diabetes, heart failure or other kidney indications should discuss it with their nephrologist rather than stop on their own.